Studies have suggested that abnormal IGFBP3 levels could disrupt this control, creating cellular conditions more favorable for cancer development [104, 105]
This product is not a drug, supplement, or therapy and is not regulated for medical, human, or veterinary application
Some of our preliminary observations in 2026 suggest that the steady, continuous delivery of a patch may actually lessen the intensity of these side effects for some patients, as it avoids the sharp peak in medication concentration that occurs a day or two after an injection
We previously showed promising one-year outcomes, 1 but questions remain about longer-term trends
The authors proposed that the increased GLP-1 levels potentiated the insulin surge and contributed to the subsequent hypoglycemia